CLINICAL RESULTS OF AB-206 IN THE TREATMENT OF URINARY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 26; no. Supplement4; pp. 130 - 134
• Main Authors: TOFUKUJI, HIDEYUKI, OKISHIO, NORIHIKO
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1978
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.26.Supplement4_130

AB-206 was administered to a total of 20 cases of genitourinary infections. The results were as follows. The subjects consisted of 11 cases of acute cystitis, 5 cases of acute prostatitis, one case of acute pyelonephritis, 2 cases of chronic pyelonephritis, and one case of chronic prostatitis. In all of these cases, AB-206 was found to be effective although the result obtained in one case of acute prostatitis was not so good. As the causative organisms, E. coli was isolated from 12 cases, Pseudomonas from 3 cases, Entero-bacter from 2 cases, and Klebsiella, Proteus and Staphylococcus epidermidis from one case each. In all but 2 of 3 cases, from which Pseudomonas was isolated, cultures became negative for organisms after treatment with AB-206. Results of treatment were assessed according to the criteria of UTI for drug efficacy evaluation of AB-206. It was found that with respect to acute cases disappearance of symptoms was observed in 76.5% and improvement in 17.6% of the cases. In 5.9% of the cases the therapeutic result was assessed as unchanged. Regarding pyuria, disappearance obtained in 76.5% and decrease in 11.8%. In 11.8% of the cases the therapeutic result was rated as unchanged with respect to this symptom. In terms of bacteriuria, conversion into negative was observed in 94.1% and decrease in 5.9% of the cases. Thus, globally the response to treatment with AB-206 was rated as excellent in 70.6%, as good in 23.5% and as poor in 5.9% of the cases. In the present study AB-206 was administered in a dosage of 750 or 1, 000 mg/day for a period of 7 to 17 days, but in none of the cases any side effects which required discontinuance or reductio n of the dosage of the drug developed.